You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

May 8, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Oncology drug spending soars

Total global spending on oncology medicines—including therapeutic treatments and supportive care—reached the $100 billion threshold in 2014, while spending on oncology drugs in the United States increased 5.3% compounded annual growth rate in 2014 to reach $42.4 billion, according to a report. » Report details

Community initiative aims to improve type 2 diabetes care in Hispanic adults

Janssen Pharmaceuticals has launched a multifaceted initiative designed to support healthcare professionals who treat the culturally-unique needs of Hispanic adults with type 2 diabetes. » Initiative details

Continuing Education

MTM essentials for asthma: Part 1

This month Drug Topics and the University of Connecticut School of Pharmacy offer a new CPE series: MTM for the patient with respiratory disease. Pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities (released April – December 2015). This month the series kicks off with MTM essentials for asthma management, covering the pathophysiology of asthma, clinical presentations of asthma, assessment methods, and nonpharmacologic management options.

To read and print the article with TEST questions, click here

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT29-YKX36.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

AbbVie hopes to advance HCV therapy for genotype 4

AbbVie's investigational hepatitis C virus (HCV) cocktail has been granted FDA priority review for the treatment of adult patients with chronic genotype 4 HCV infection—the first investigational drug combination for GT4 infection, which accounts for about 6% of HCV cases in the United States. » Read more

 

RELATED ARTICLES

Study: Drug costs for hereditary angioedema tripled in 2 years

Report: Diabetes drives traditional drug trend, specialty trend increases 20%

RESOURCES

Latest Clinical News

Powered by Modern Medicine UBM  logo

UBM MEDICA